SCHEMBL15035359

SCHEMBL15035359

CCC(CC)c1cc2cnc(Nc3ccc(OC4CCN(C)CC4)cc3)nc2n(C2Cc3ccccc3NC2=O)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 1/20 0.44
AXL P30530 5/20 0.41
CDK2 P24941 6/20 0.38
CCNA2 P20248 5/20 0.38
AURKA O14965 2/20 0.38
WEE1 P30291 2/20 0.38
TTK P33981 1/20 0.38
FGFR1 P11362 3/20 0.38
SRC P12931 3/20 0.38
PDGFRB P09619 2/20 0.38
PDGFRA P16234 1/20 0.38
CDK4 P11802 3/20 0.38
CCND1 P24385 3/20 0.38
RIPK2 O43353 1/20 0.38
ACVR1 Q04771 1/20 0.38
NOD2 Q9HC29 1/20 0.38
TNK2 Q07912 1/20 0.38
CCNA1 P78396 1/20 0.37
FGFR2 P21802 1/20 0.37
FGFR4 P22455 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15035464 0.84 CAMK2D (0.43) CAMK2DAXLCDK2CCNA2AURKA
SCHEMBL15035566 0.83 CAMK2D (0.45) CAMK2DAXLCDK2CCNA2AURKA
SCHEMBL15035444 0.78 CDK4 (0.52) CDK2CCNA2AURKAWEE1FGFR1
SCHEMBL15041307 0.74 CDK4 (0.52) CDK2CCNA2AURKAFGFR1PDGFRB
SCHEMBL15034942 0.74 CAMK2D (0.46) CAMK2DAXLCDK2CCNA2AURKA
SCHEMBL15035289 0.74 CDK4 (0.44) CDK2CCNA2AURKAWEE1FGFR1
SCHEMBL15041353 0.73 CAMK2D (0.45) CAMK2DAXLCDK2CCNA2AURKA
SCHEMBL15035047 0.73 CAMK2D (0.45) CAMK2DAXLCDK2CCNA2AURKA
SCHEMBL15035911 0.73 CAMK2D (0.45) CAMK2DAXLCDK2CCNA2AURKA
SCHEMBL15035383 0.72 CDK4 (0.39) CDK2CCNA2FGFR1PDGFRBCDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 CAMK2D 469/4885AXL 1075/4885CDK2 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.